This could suggest that different synapses have unique signatures of tau phosphorylation patterns in AD, or that there are technical considerations (e.g. masked antibody binding sites) that make it harder to resolve both epitopes when they co-localise. The gene discussed is MAPT; the disease is Alzheimer disease.